STUDY QUESTION Is severe early ovarian hyperstimulation syndrome (OHSS) completely prevented with the GnRH agonist trigger and 1500 IU hCG luteal rescue protocol? SUMMARY ANSWER Severe early OHSS can occur even after the GnRH agonist trigger and 1500 IU hCG luteal rescue protocol. WHAT IS KNOWN ALREADY Prior studies including over 200 women who received the GnRH agonist trigger and 1500 hCG...

OBJECTIVE Ovarian hyperstimulation syndrome (OHSS) is a serious iatrogenic condition, predominantly related to the hormone used to induce oocyte maturation during IVF treatment. Kisspeptin is a hypothalamic neuropeptide that has recently been demonstrated to safely trigger final oocyte maturation during IVF treatment even in women at high risk of OHSS. However, to date, the safety of kisspeptin...

The December 2002 issue of Fertility and Sterility contains three papers on the ovarian hyperstimulation syndrome (OHSS), including a commentary by Dr. Meldrum (1). Dr. Meldrum summarizes his paper by stating that “we can . . . move on to developing new ways to prevent and treat this dangerous condition.” Undoubtedly, the fertility community is still plagued by this complication of ovarian stim...

This study was performed to analyze retrospectively outcomes of stimulated in vitro fertilization (IVF) cycles where the gonadotropin-releasing hormone (GnRH) antagonist was omitted on ovulation triggering day. A total of 92 consecutive IVF cycles were included in 65 women who are undergoing ovarian stimulation with recombinant FSH. A GnRH antagonist, cetrorelix 0.25 mg/day, was started when le...

BACKGROUND Gonadotropin-releasing hormone (GnRH) agonist triggering plus 1,500 IU human chorionic gonadotropin (hCG) supplementation protocol was previously claimed effective in reducing the ovarian hyperstimulation syndrome (OHSS) incidence in high responders. METHODS This retrospective study included women with polycystic ovarian (PCO) morphology who were at high risk of OHSS and were given...

Background: This study intends to present the role of rescue in vitro maturation (IVM) in polycystic ovarian syndrome(PCOS) patients undergoing in vitro fertilization (IVF) treatment who have inappropriate responses to ovarianstimulation.Materials and Methods: This was a retrospective case series study of five PCOS patients undergoing IVF treatmentconsidered for cycle ca...

This study reports 21 IVF cases with excessive ovarian response, who received gonadotrophin-releasing hormone agonist (GnRHa) triggering for final oocyte maturation, followed by a human chorionic gonadotrophin (HCG)-based, progesterone-free, luteal support, individually timed ('luteal coasting') according to endogenous luteal progesterone concentrations. One patient developed a brief early-onse...